课题基金 / 基金详情

Mab immunotherapies for myeloid leukemia patients with germline or somatic RUNX1 mutations.

Mab immunotherapies for myeloid leukemia patients with germline or somatic RUNX1 mutations.
用于具有种系或体细胞 RUNX1 突变的骨髓性白血病患者的 Mab 免疫疗法。
批准号:
nhmrc : GNT1145278
负责人:
A/Pr Ian Lewis
金额:
$76.7万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2018
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2018-01-01 至 --

项目摘要

项目成果

A/Pr Ian Lewis的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mab immunotherapies for myeloid leukemia patients with germline or somatic RUNX1 mutations.
  • 批准号:
    nhmrc : 1145278
  • 项目类别:
    Project Grants
  • 资助金额:
    $51.86万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Ian Lewis
  • 依托单位:
FANC gene mutations in Acute Myeloid Leukaemia biology and treatment
  • 批准号:
    nhmrc : 1145391
  • 项目类别:
    Project Grants
  • 资助金额:
    $60.9万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Ian Lewis
  • 依托单位:
FANC gene mutations in Acute Myeloid Leukaemia biology and treatment
  • 批准号:
    nhmrc : GNT1145391
  • 项目类别:
    Project Grants
  • 资助金额:
    $90.08万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Ian Lewis
  • 依托单位:
Co-operation between GATA2 mutation or expression and RAS signalling in AML
  • 批准号:
    nhmrc : 1086302
  • 项目类别:
    Project Grants
  • 资助金额:
    $57.38万
  • 财政年份:
    2015
  • 负责人:
    A/Pr Ian Lewis
  • 依托单位:
海外基金